KPRX
Kiora Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$2.15
+0.03 (+1.42%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.02M | 1.95M | 2.03M |
| Net Income | 297.3K | 336.4K | 321.2K |
| EPS | — | — | — |
| Profit Margin | 14.7% | 17.3% | 15.8% |
| Rev Growth | +18.3% | -4.0% | +17.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 2.46M | 2.15M | 2.24M |
| Total Equity | 2.51M | 2.54M | 2.59M |
| D/E Ratio | 0.98 | 0.84 | 0.87 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 553.0K | 564.5K | 565.8K |
| Free Cash Flow | 382.2K | 437.5K | 326.8K |